Sugi Predict

Sugi Predict / Compounds / SCHEMBL3319396

SCHEMBL3319396

SCHEMBL3319396

CCOC(=O)c1ccc(-c2nc(Nc3cc(C(=O)NC4CC4)ccc3C)sc2C(=O)NCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DHODH Q02127 13/20 0.47
▸ MAPK14 Q16539 3/20 0.46
▸ MAPT P10636 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ MAPK11 Q15759 2/20 0.43
▸ ADORA2A P29274 2/20 0.42
▸ ADORA1 P30542 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ PPARG P37231 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NCOA2 Q15596 1/20 0.42
▸ NCOA1 Q15788 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27635999 0.92 MAPK14 (0.50) DHODHMAPK14MAPTTP53RXFP1
SCHEMBL3347281 0.92 MAPT (0.49) DHODHMAPK14MAPTTP53RXFP1
SCHEMBL3346606 0.91 MAPT (0.49) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3313848 0.91 MAPK14 (0.47) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3345188 0.91 MAPK14 (0.49) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3345794 0.91 MAPK14 (0.53) DHODHMAPK14MAPTTP53MAPK11
SCHEMBL3345525 0.91 MAPK14 (0.49) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3351894 0.90 MAPK14 (0.52) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3319041 0.90 MAPK14 (0.49) MAPK14MAPTTP53RXFP1LMNA
SCHEMBL3317134 0.90 MAPK14 (0.49) MAPK14MAPTTP53RXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US claimed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US claimed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP claimed
EP-1635824-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS Novartis AG (CH) 2006-03-22 — — EP claimed
WO-2005000298-A2 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2005-01-06 — — WO claimed
US-20040254236-A1 P-38 inhibitors NOVARTIS AG (CH) 2004-12-16 — — US claimed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-7652044-B2 P-38 inhibitors NOVARTIS A.G. (CH) 2010-01-26 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
US-20100004298-A1 P-38 INHIBITORS DONG QING 2010-01-07 — — US disclosed
EP-1635824-B1 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS NOVARTIS AG (CH) 2009-08-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004298-A1 P-38 INHIBITORS MAPK8, MAPK1, MAP3K8 DHODH 4301/4885MAPK14 21/4885MAPT 725/4885
US-20040254236-A1 P-38 inhibitors MAPK8, MAP3K8, MAPK1 DHODH 4223/4885MAPK14 12/4885MAPT 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.